Pancreatic cancer: Stroma and its current and emerging targeted therapies

Janaiah Kota, Julie Hancock, Jason Kwon, Murray Korc

Research output: Contribution to journalShort survey

44 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human malignancies with a 5-year survival rate of 8%. Dense, fibrotic stroma associated with pancreatic tumors is a major obstacle for drug delivery to the tumor bed and plays a crucial role in pancreatic cancer progression. Targeting stroma is considered as a potential therapeutic strategy to improve anti-cancer drug efficacy and patient survival. Although numerous stromal depletion therapies have reached the clinic, they add little to overall survival and are often associated with toxicity. Furthermore, increasing evidence suggests the anti-tumor properties of stroma. Its complete ablation enhanced tumor progression and reduced survival. Consequently, efforts are now focused on developing stromal-targeted therapies that normalize the reactive stroma and avoid the extremes: stromal abundance vs. complete depletion. In this review, we summarized the state of current and emerging anti-stromal targeted therapies, with major emphasis on the role of miRNAs in PDAC stroma and their potential use as novel therapeutic agents to modulate PDAC tumor-stromal interactions.

Original languageEnglish (US)
Pages (from-to)38-49
Number of pages12
JournalCancer Letters
Volume391
DOIs
StatePublished - Apr 10 2017

Fingerprint

Pancreatic Neoplasms
Neoplasms
Adenocarcinoma
Therapeutics
Survival
MicroRNAs
Pharmaceutical Preparations
Survival Rate

Keywords

  • miRNAS
  • Pancreatic Cancer
  • Stroma
  • Targeted therapies
  • Tumor microenvironment

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Pancreatic cancer : Stroma and its current and emerging targeted therapies. / Kota, Janaiah; Hancock, Julie; Kwon, Jason; Korc, Murray.

In: Cancer Letters, Vol. 391, 10.04.2017, p. 38-49.

Research output: Contribution to journalShort survey

Kota, Janaiah ; Hancock, Julie ; Kwon, Jason ; Korc, Murray. / Pancreatic cancer : Stroma and its current and emerging targeted therapies. In: Cancer Letters. 2017 ; Vol. 391. pp. 38-49.
@article{613d6535a6c141978414867b66426e67,
title = "Pancreatic cancer: Stroma and its current and emerging targeted therapies",
abstract = "Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human malignancies with a 5-year survival rate of 8{\%}. Dense, fibrotic stroma associated with pancreatic tumors is a major obstacle for drug delivery to the tumor bed and plays a crucial role in pancreatic cancer progression. Targeting stroma is considered as a potential therapeutic strategy to improve anti-cancer drug efficacy and patient survival. Although numerous stromal depletion therapies have reached the clinic, they add little to overall survival and are often associated with toxicity. Furthermore, increasing evidence suggests the anti-tumor properties of stroma. Its complete ablation enhanced tumor progression and reduced survival. Consequently, efforts are now focused on developing stromal-targeted therapies that normalize the reactive stroma and avoid the extremes: stromal abundance vs. complete depletion. In this review, we summarized the state of current and emerging anti-stromal targeted therapies, with major emphasis on the role of miRNAs in PDAC stroma and their potential use as novel therapeutic agents to modulate PDAC tumor-stromal interactions.",
keywords = "miRNAS, Pancreatic Cancer, Stroma, Targeted therapies, Tumor microenvironment",
author = "Janaiah Kota and Julie Hancock and Jason Kwon and Murray Korc",
year = "2017",
month = "4",
day = "10",
doi = "10.1016/j.canlet.2016.12.035",
language = "English (US)",
volume = "391",
pages = "38--49",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Pancreatic cancer

T2 - Stroma and its current and emerging targeted therapies

AU - Kota, Janaiah

AU - Hancock, Julie

AU - Kwon, Jason

AU - Korc, Murray

PY - 2017/4/10

Y1 - 2017/4/10

N2 - Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human malignancies with a 5-year survival rate of 8%. Dense, fibrotic stroma associated with pancreatic tumors is a major obstacle for drug delivery to the tumor bed and plays a crucial role in pancreatic cancer progression. Targeting stroma is considered as a potential therapeutic strategy to improve anti-cancer drug efficacy and patient survival. Although numerous stromal depletion therapies have reached the clinic, they add little to overall survival and are often associated with toxicity. Furthermore, increasing evidence suggests the anti-tumor properties of stroma. Its complete ablation enhanced tumor progression and reduced survival. Consequently, efforts are now focused on developing stromal-targeted therapies that normalize the reactive stroma and avoid the extremes: stromal abundance vs. complete depletion. In this review, we summarized the state of current and emerging anti-stromal targeted therapies, with major emphasis on the role of miRNAs in PDAC stroma and their potential use as novel therapeutic agents to modulate PDAC tumor-stromal interactions.

AB - Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human malignancies with a 5-year survival rate of 8%. Dense, fibrotic stroma associated with pancreatic tumors is a major obstacle for drug delivery to the tumor bed and plays a crucial role in pancreatic cancer progression. Targeting stroma is considered as a potential therapeutic strategy to improve anti-cancer drug efficacy and patient survival. Although numerous stromal depletion therapies have reached the clinic, they add little to overall survival and are often associated with toxicity. Furthermore, increasing evidence suggests the anti-tumor properties of stroma. Its complete ablation enhanced tumor progression and reduced survival. Consequently, efforts are now focused on developing stromal-targeted therapies that normalize the reactive stroma and avoid the extremes: stromal abundance vs. complete depletion. In this review, we summarized the state of current and emerging anti-stromal targeted therapies, with major emphasis on the role of miRNAs in PDAC stroma and their potential use as novel therapeutic agents to modulate PDAC tumor-stromal interactions.

KW - miRNAS

KW - Pancreatic Cancer

KW - Stroma

KW - Targeted therapies

KW - Tumor microenvironment

UR - http://www.scopus.com/inward/record.url?scp=85010843558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010843558&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2016.12.035

DO - 10.1016/j.canlet.2016.12.035

M3 - Short survey

C2 - 28093284

AN - SCOPUS:85010843558

VL - 391

SP - 38

EP - 49

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

ER -